Core Insights - The company, Lideman, reported that as of October 31, 2025, the number of shareholders reached 33,688 [2] Company Summary - Lideman's shareholder count is projected to be 33,688 by the end of October 2025 [2]

Core Viewpoint - Lidman has experienced a significant stock price increase of 51.84% year-to-date, despite a recent decline in the last five and twenty trading days [2]. Company Overview - Beijing Lidman Biochemical Co., Ltd. was established on November 5, 1997, and listed on February 16, 2012. The company specializes in in vitro diagnostic reagents (biochemical, immunological, molecular), diagnostic instruments, and biochemical raw materials [2]. - The revenue composition of Lidman includes: in vitro diagnostic reagents 67.84%, diagnostic instruments 14.17%, other (property leasing/management, etc.) 13.21%, and biochemical raw materials 4.78% [2]. Stock Performance - As of October 31, Lidman's stock price was 7.44 CNY per share, with a market capitalization of 4.047 billion CNY. The stock saw a trading volume of 47.6122 million CNY and a turnover rate of 1.19% [1]. - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) four times this year, with the most recent appearance on August 8 [2]. Financial Performance - For the period from January to September 2025, Lidman reported a revenue of 252 million CNY, a year-on-year decrease of 10.49%. The net profit attributable to the parent company was -7.1348 million CNY, a decrease of 765.83% year-on-year [2]. - The company has distributed a total of 143 million CNY in dividends since its A-share listing, with 5.4401 million CNY distributed in the last three years [3]. Shareholder Information - As of October 20, 2025, Lidman had 33,600 shareholders, an increase of 1.96% from the previous period. The average circulating shares per person decreased by 1.92% to 16,170 shares [2]. - The top ten circulating shareholders include a new entrant, the Medical Device ETF (159883), holding 2.0113 million shares, while Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund (004685) and Huaxia CSI 500 Index Enhanced A (007994) have exited the top ten [3].

证券代码：300289 证券简称：利德曼 公告编号：2025-050 北京利德曼生化股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本次重大资产重组的基本情况 北京利德曼生化股份有限公司（以下简称"公司"或"上市公 司"）正在筹划以支付现金方式收购北京先声祥瑞生物制品股份有限 公司（以下简称"目标公司"）部分股东持有的目标公司合计不超过 70%的股份（以下简称"本次交易"）。本次交易前，公司未持有目标 公司的股份；本次交易完成后，公司将取得目标公司控制权，目标公 司将成为公司的控股子公司。 根据初步测算，本次交易预计构成《上市公司重大资产重组管理 办法》规定的重大资产重组。本次交易不涉及上市公司发行股份，不 构成关联交易，也不会导致公司控制权变更。 特此公告。 北京利德曼生化股份有限公司 截至本公告披露日，公司持续推进上述筹划重大资产重组的具体 事宜，根据相关规定正在组织各中介机构积极开展对目标公司的尽职 调查以及审计、评估等工作，并就重大资产重组事项同各相关方持续 沟通协商，目前交易相关方尚未签署正式交易文件 ...

Core Insights - Lideman (300289.SZ) reported a total operating revenue of 252 million yuan for Q3 2025, ranking 66th among disclosed peers, which represents a decrease of 29.58 million yuan or 10.49% year-on-year [1] - The company's net profit attributable to shareholders was -7.13 million yuan, ranking 63rd among peers, a decline of 8.21 million yuan or 765.83% year-on-year [1] - Operating cash flow showed a net inflow of 9.68 million yuan, ranking 61st among peers, down by 37.01 million yuan or 79.26% year-on-year [1] Financial Ratios - The latest debt-to-asset ratio is 5.33%, ranking 3rd among peers, with an increase of 0.11 percentage points from the previous quarter and 0.23 percentage points from the same period last year [3] - The latest gross profit margin is 49.51%, ranking 44th among peers, down by 2.51 percentage points from the previous quarter and 4.65 percentage points year-on-year [3] - The latest return on equity (ROE) is -0.43%, ranking 63rd among peers, a decrease of 0.49 percentage points year-on-year [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share is -0.01 yuan, ranking 61st among peers, a decrease of 0.02 yuan or 755.00% year-on-year [3] - The total asset turnover ratio is 0.14 times, ranking 67th among peers, down by 0.01 times or 5.57% year-on-year [3] - The inventory turnover ratio is 1.47 times, ranking 43rd among peers, an increase of 0.07 times or 5.25% year-on-year [3] Shareholder Structure - The number of shareholders is 32,900, with the top ten shareholders holding 271 million shares, accounting for 49.79% of the total share capital [3] - The largest shareholder is Guangzhou High-tech Zone Technology Holding Group Co., Ltd., holding 46.35% [3]

Group 1 - The company announced the appointment of Ms. Yaozi as a member of the sixth board of directors' nomination committee [2] - Mr. Li Xiangguo has been re-elected as a member of the sixth board of directors' audit committee [2]

Core Viewpoint - Lideman (300289) announced the appointment of Mr. Liao Zihua as a candidate for the non-independent director of the sixth board of directors [1] Group 1 - The company's board of directors approved the supplementary election of Mr. Liao Zihua [1]

Core Viewpoint - Lideman (300289.SZ) reported a decline in revenue and a net loss for the first three quarters of 2025, indicating financial challenges faced by the company [1] Financial Performance - The company's operating revenue for the first three quarters was 252 million yuan, representing a year-on-year decrease of 10.49% [1] - The net loss attributable to shareholders of the listed company was 7.1348 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 14.5613 million yuan [1] - The basic loss per share was 0.0131 yuan [1]

证券代码：300289 证券简称：利德曼 公告编号：2025-048 北京利德曼生化股份有限公司 关于修订《公司章程》及附件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）于 2025 年 10 月 28 日召开第六届董事会第六次会议，审议通过了《关于修订<公司章程> 及附件的议案》，现将相关事项公告如下： 一、修订《公司章程》及附件的原因及依据 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司章程指引》《上市公司股东会规则》《上市公司独立董事管理办法》《深 圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》《关于新〈公司法〉配套制度 规则实施相关过渡期安排》等相关法律、法规、规范性文件的规定，结 合公司实际情况，公司不再设置监事会，由董事会审计委员会行使监事 会职权，同时废止《监事会议事规则》；董事会同意修订《公司章程》及 附件《股东会议事规则》，并重新制定《董事会议事规则》。 本事项尚须提交公司股东大会审议。 二、《公司章程》及附 ...

关于补选董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）于2025年10月28 日召开第六届董事会第六次会议，审议通过《关于补选廖子华先生为公 司第六届董事会非独立董事的议案》，具体内容公告如下： 根据公司控股股东广州高新区科技控股集团有限公司（持股比例 46.35%）的提名，经董事会提名委员会对董事候选人的任职资格审查 通过，董事会同意补选廖子华先生（简历附后）作为公司第六届董事会 非独立董事候选人，并同意将该议案提交至公司2025年第一次临时股东 大会审议，其任期自公司股东大会审议通过之日起至第六届董事会任期 届满时止。 本次补选非独立董事后，公司董事会中兼任高级管理人员以及由职 工代表担任的董事人数总计未超过公司董事总数的二分之一。 证券代码：300289 证券简称：利德曼 公告编号：2025-047 北京利德曼生化股份有限公司 北京利德曼生化股份有限公司 董 事 会 2025 年 10 月 28 日 附：非独立董事候选人简历 廖子华，男，1991 年 10 月生，研究生学历，中国国籍，无境外长 ...

关于补选董事会提名委员会委员和审计委员会委员 的公告 证券代码：300289 证券简称：利德曼 公告编号：2025-045 北京利德曼生化股份有限公司 特此公告。 北京利德曼生化股份有限公司 董 事 会 2025 年 10 月 28 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 北京利德曼生化股份有限公司（以下简称"公司"）原董事郑允新 先生已于2025年9月24日辞去公司董事职务，同时一并辞去公司第六届 董事会提名委员会委员和审计委员会委员职务。根据《公司法》及《公 司章程》等相关规定，经公司第六届董事会第六次会议审议通过，董事 会同意补选尧子女士担任公司第六届董事会提名委员会委员、补选李相 国先生为公司第六届董事会审计委员会委员，任期自董事会审议通过之 日起至第六届董事会届满时止。 本次补选完成后，公司第六届董事会提名委员会组成情况为：张志 谦先生（召集人）、尧子女士（委员）、杨格先生（委员）；公司第六 届董事会审计委员会组成情况为：杨格先生（召集人）、李相国先生（委 员）、安娜女士（委员）。 ...